Trials / Unknown
UnknownNCT04088513
Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)
A Randomized, Double-blind, Active-Controlled Trial Comparing the Safety and Efficacy of Aspirin Versus Clopidogrel in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 440 (estimated)
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Aspirin was reported to induce hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency on some occasions, while still widely uesd for stroke prevention. The SAST trial is designed to evaluate the safety and efficacy of aspirin in patients this enzyme disorder.The primary purpose of the trial is to evaluate the hemolytic effects of a 3-month regimen of aspirin 100mg/d versus a 3-month regimen of clopidogrel 75mg/d.
Detailed description
This SAST trial is a prospective, multicenter, randomized, double-blind trial.440 acute ischemic stroke (AIS) patients with G6PD deficiency will be randomized to receive a 3-month regimen of aspirin 100mg/d or clopidogrel 75mg/d. The primary end point is the proportion of protocol-defined hemolysis at 90 days. Protocol-defined hemolysis is defined as one or more of the following conditions: a) Hemoglobin level declined ≥2.5 g/dL from baseline, meanwhile ruling out bleeding events. b) Hemoglobin level declined ≥25% from baseline, meanwhile ruling out bleeding events. c) Clinically relevant hemolytic events, could manifested as fatigue, back pain, anemia, dark urine and jaundice. The study consists of five visits including the day of randomization, day 4, day10±3days, day27±3days, day90±7days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin | This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days. |
| DRUG | Clopidogrel | This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days. |
Timeline
- Start date
- 2020-01-22
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2019-09-12
- Last updated
- 2022-03-16
Locations
19 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04088513. Inclusion in this directory is not an endorsement.